Browse the evidence

GLP-1-Rezeptoragonisten sollten als Krankenkassenleistung angeboten werden.

Praktiker sollten die Möglichkeit in Betracht ziehen, GLP-1-Rezeptoragonisten in die Krankenkassenleistungen aufzunehmen.

Once-monthly maridebart is associated with HbA1c reductions of approximately 1.2–1.6 percentage points.

Clinicians can anticipate improvements in glycemic control with maridebart therapy.

Among 7,493 members, rates of persistence and adherence to treatment were 60.8% and 60.1%, respectively.

Practitioners should note that adherence to GLP-1 therapies is moderate in this population.

Member-specific factors associated with lower rates of persistence and adherence included male sex, age (<40 years), diabetes, and a lack of weight-related comorbidities.

Understanding these factors can help tailor interventions to improve adherence.

Incretin-based therapies are effective but present limitations for long-term obesity management.

Practitioners should be aware of the limitations of incretin therapies in long-term obesity management.

Obesity without metabolic abnormalities increases the risk of atherosclerotic cardiovascular disease (ASCVD) by 46% in men and 34% in women compared to those with normal BMI.

Practitioners should recognize that obesity, even without metabolic abnormalities, poses significant cardiovascular risks.

Obesity is associated with increased risk of heart failure (HF), with a 63% increase in men and a 69% increase in women compared to those with normal BMI.

Practitioners should be aware of the significant risk of heart failure in obese patients, regardless of metabolic health.

Tirzepatide led to a greater reduction in median triglyceride levels compared with semaglutide.

Tirzepatide may be preferred for patients needing significant triglyceride reduction.

Both groups achieved comparable reductions in body weight after 12 weeks.

Weight loss can be achieved with both dietary interventions during Tirzepatide therapy.

Relative preservation of fat-free mass, muscle strength, and resting metabolic rate was observed in one dietary context.

Choosing the right dietary context may help preserve muscle and metabolic health during weight loss.

Short-term changes in glycaemic parameters were statistically associated with concurrent changes in fat-free mass, muscle strength, and resting metabolic rate.

Monitoring glycaemic parameters may provide insights into metabolic health during weight loss.

Discontinuation of GLP-1 receptor agonists is associated with substantial weight regain of 60%-90% within one year.

Clinicians should anticipate significant weight regain in patients discontinuing GLP-1RA therapy.

Early discontinuation of GLP-1RA therapy is associated with increased risks of coronary artery disease and heart failure.

Clinicians should be aware of the cardiovascular risks when patients discontinue GLP-1RA therapy early.

Placebo-adjusted weight loss was significantly lower in T2D versus obesity trials (pooled ratio: 0.61, 95% C.I. 0.56; 0.67).

Clinicians should consider that patients with T2D may experience less weight loss from incretin therapies compared to those with obesity alone.

Study-level diabetes status, age, BMI, sex distribution, ethnicity, and cardiometabolic comorbidities significantly correlated with BW loss at univariate analysis.

Understanding these correlates can help tailor weight loss strategies in clinical practice.

The addition of testosterone undecanoate improved insulin sensitivity and sexual health compared to tirzepatide monotherapy.

Clinicians should consider the potential benefits of testosterone therapy on metabolic and sexual health in this patient group.

GLP-1RA therapy was associated with significant weight, glycemic, and renal benefits that were attenuated in Black adults.

It is important for practitioners to recognize that GLP-1RA therapy may have varying effectiveness across different racial groups.

On days participants reported higher-than-average incidental affect, intention, and self-monitoring, they were more likely to engage in resistance training.

Practitioners should consider the role of daily emotional states and self-monitoring in promoting resistance training among GLP-1 users.

Participants with higher levels of incidental affect, intention, and self-monitoring consistently showed a greater likelihood of participating in resistance training.

Encouraging self-monitoring and positive emotional states may enhance resistance training adherence.

On days with higher-than-average affective attitude and perceived capabilities, participants were more likely to intend to engage in resistance training.

Fostering positive attitudes and self-efficacy can be beneficial in promoting resistance training intentions.

Incretin-based therapies such as GLP-1 RA improve symptoms, exercise capacity, congestion, and reduce heart failure events in obesity-related HFpEF.

Practitioners may consider incretin-based therapies as a treatment option for improving outcomes in patients with obesity-related HFpEF.

Incretin-based therapies lead to reduced ectopic fat depositions in multiple organs and favourable cardiac remodelling.

Incretin-based therapies may be effective in reducing harmful fat deposits and improving heart structure in affected patients.

Metabolic and bariatric surgery (MBS) achieves superior comorbidity remission compared to intensive medical therapy.

MBS should be considered as a primary treatment option for patients with severe obesity and related comorbidities.

Laparoscopic Roux-en-Y gastric bypass provides superior long-term remission of dyslipidaemia, hypertension, and gastro-oesophageal reflux disease compared to laparoscopic sleeve gastrectomy.

Surgeons should consider Roux-en-Y gastric bypass for patients with specific comorbidities.